Ginkgo Bioworks Holdings (DNA) Debt Ratio (2020 - 2021)
Ginkgo Bioworks Holdings (DNA) reported Debt Ratio of 0.0 for Q2 2021, up 58.05% quarter-over-quarter from 0.0 in Q4 2020.
Ginkgo Bioworks Holdings (DNA) Debt Ratio (2020 - 2021) Analysis & Trends
Ginkgo Bioworks Holdings has reported Debt Ratio for 2 years, with the latest figure at 0.0 in Q2 2021.
- For the quarter ending Q2 2021, Debt Ratio changed N/A year-over-year to 0.0; the trailing twelve-month figure through Jun 2021 stood at 0.0 (changed N/A YoY), and the FY2020 full-year result was 0.0, changed N/A from the prior year.
- Debt Ratio for Q2 2021 stood at 0.0, up from 0.0 in the prior quarter.
- The five-year high for Debt Ratio was 0.0 in Q2 2021, with the low at 0.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 0.18 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Ginkgo Bioworks Holdings | 480.68 Mn | 480.68 Mn | 16.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 0.00 |
| Dec 31, 2020 | 0.00 |